Benign Prostatic Hyperplasia Clinical Trials 2023

Benign Prostatic Hyperplasia Clinical Trials 2023

Benign Prostatic Hyperplasia research studies recruiting patients in 2023 need your help. Receive premium care & cutting edge treatments by enrolling in benign prostatic hyperplasia clinical trials today.

Trials for Enlarged Prostate Patients

Trials for Lower Urinary Tract Symptoms Patients

Trials With No Placebo

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to benign prostatic hyperplasia

What are the top hospitals conducting benign prostatic hyperplasia research?

When it comes to cutting-edge clinical trials addressing benign prostatic hyperplasia (BPH), hospitals across the United States are making notable contributions. In Cleveland, Ohio, University Hospitals Cleveland Medical Center takes the lead with one active BPH trial and an equally impressive history of conducting a single trial for this condition thus far. This medical center has demonstrated its commitment to advancing research in BPH since recording its first trial in 2023. Similarly, UH Brainard Medical Bldg in Lyndhurst and UH Regional Hospitals - Richmond Campus in Richmond Heights have also embarked on their own respective active BPH trials and hold a record of one completed trial each—both initiated in 2023.

Moving northward to Thunder Bay Regional Health Sciences Centre situated in Thunder Bay, Canada, we find another medical facility dedicated to exploring solutions for individuals affected by BPH. With one ongoing clinical trial focused on this condition and having commenced their inaugural investigation back in 2022, this center is actively contributing to expanding our understanding of potential treatments for the condition.

Finally, located southwards all away down into Hialeah is Urology Specialist Group where they too are pioneering similar efforts towards finding resolutions tending only one current clinical experiment alongside having successfully conducted singular such investigations since way back as 2020.

These hospitals represent beacons of hope for those suffering from BPH while exemplifying dedication towards advancements within urological health care. Although there may appear few active trials presently underway across these institutions collectively, it's essential to acknowledge that every initiative contributes substantially toward enhanced patient outcomes and better quality of life moving forward

Which are the best cities for benign prostatic hyperplasia clinical trials?

For benign prostatic hyperplasia clinical trials, several cities have emerged as leaders in research and development. Thunder Bay, Ontario takes the lead with 2 active trials investigating treatments such as Thulium Fibre Laser and Top-Down HoLEP. Following closely behind is Cleveland, Ohio, along with its neighboring cities Lyndhurst and Richmond Heights, each hosting 1 active trial focused on Intravesical Botox injection among other interventions. Additionally, Hialeah, Florida joins the ranks with 1 ongoing trial exploring SoracteLite(TM) TPLA for BPH. These cities offer individuals affected by benign prostatic hyperplasia opportunities to participate in cutting-edge clinical trials that strive for improved treatment options and better quality of life.

Which are the top treatments for benign prostatic hyperplasia being explored in clinical trials?

Clinical trials exploring potential treatments for benign prostatic hyperplasia (BPH) have brought several promising options to the forefront. Prostate Artery Embolization, a procedure designed to shrink the prostate gland by blocking its blood supply, is currently being tested in two active trials and has been involved in five all-time BPH trials since its introduction in 2014. Intravesical Botox injection, a minimally invasive treatment that involves injecting botulinum toxin directly into the bladder wall, shows promise with one active trial and one all-time trial dedicated to BPH research since its first listing in 2023. Thulium Fibre Laser therapy and SoracteLite(TM) TPLA are also undergoing investigation through clinical trials for their efficacy against BPH, each with one active trial and one all-time study focused on this condition. As these studies progress, they provide hope for improved management of benign prostatic hyperplasia.

What are the most recent clinical trials for benign prostatic hyperplasia?

Recent clinical trials offer promising advancements in the treatment of benign prostatic hyperplasia (BPH). A Phase 4 trial explores a new treatment group specifically tailored for BPH, potentially providing improved outcomes for patients. Additionally, SoracteLite(TM) TPLA is being investigated in a Phase 1 study as a potential therapeutic option for BPH. These innovative trials aim to address the challenges associated with this condition and enhance patient care.

What benign prostatic hyperplasia clinical trials were recently completed?

Recently completed clinical trials for benign prostatic hyperplasia have provided valuable insights into potential treatment options. In September 2019, Urovant Sciences GmbH successfully concluded a trial investigating the efficacy of Vibegron in addressing this condition. Similarly, another trial sponsored by Urovant Sciences GmbH reached completion in March 2019 and also focused on evaluating the effects of Vibegron. These important studies shed light on the ongoing efforts to find innovative therapeutic approaches for individuals with benign prostatic hyperplasia.